𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Maximizing the Benefit: Risk Ratio of Levodopa Therapy in Parkinson's Disease

✍ Scribed by Mildred D. Gottwald

Book ID
115047638
Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
235 KB
Volume
19
Category
Article
ISSN
0277-0008

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Botulinum toxin type A for Levodopa-indu
Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: Unfavorable risk-benefit ratio
✍ Alberto J. Espay; Jennifer E. Vaughan; Rakesh Shukla; Maureen Gartner; Alok Saha πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 880 KB

originating from the peripheral rather than central retina. Correspondingly, VEP was also reported to be normal in MSA patients as it measures activity mainly originating from the central visual field. 7 Future studies will have to determine whether MSA patients show predominantly peripheral visual

Parkinson's disease, levodopa-use and th
Parkinson's disease, levodopa-use and the risk of melanoma
✍ J.-D. Vermeij; A. Winogrodzka; J. Trip; W.E.J. Weber πŸ“‚ Article πŸ“… 2009 πŸ› Elsevier Science 🌐 English βš– 98 KB

Since the early 1970s, the literature has suggested an association between Parkinson's Disease (PD) and/ or levodopa-use and an increased risk for the development of malignant melanoma. In some countries, this possible association has even led to a warning in the drug insert leaflet of the possible